Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Cash & Current Investments (2016 - 2026)

Sensus Healthcare has reported Cash & Current Investments over the past 11 years, most recently at $22.1 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments changed 0.12% year-over-year to $22.1 million; the TTM value through Dec 2025 reached $22.1 million, changed 0.12%, while the annual FY2025 figure was $22.1 million, 0.12% changed from the prior year.
  • Cash & Current Investments for Q4 2025 was $22.1 million at Sensus Healthcare, down from $24.5 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $37.6 million in Q3 2022 and troughed at $13.7 million in Q1 2021.
  • A 5-year average of $21.9 million and a median of $21.3 million in 2023 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: surged 140.48% in 2022 and later plummeted 45.48% in 2023.
  • Year by year, Cash & Current Investments stood at $14.5 million in 2021, then soared by 75.77% to $25.5 million in 2022, then dropped by 9.29% to $23.1 million in 2023, then dropped by 4.72% to $22.1 million in 2024, then increased by 0.12% to $22.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for SRTS at $22.1 million in Q4 2025, $24.5 million in Q3 2025, and $22.2 million in Q2 2025.